Clinical Trials
2 trialsNCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01753713 2017-12-12
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed